Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2010-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01125904
- Locations
- 🇺🇸
Pfizer Investigational Site, Woburn, Massachusetts, United States
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT01121588
- Locations
- 🇺🇸
Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 122
- Registration Number
- NCT00939770
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00828919
- Locations
- 🇮🇹
Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo, Milano, Italy
🇨🇿Nemocnice Na Bulovce, Praha, Czechia
🇫🇷Hopital de la Pitie Salpetriere, Paris Cedex 13, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.